

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 9, 2021**

**Acadia Pharmaceuticals Inc.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-50768**  
(Commission  
File Number)

**06-1376651**  
(IRS Employer  
Identification No.)

**12830 El Camino Real, Suite 400**  
**San Diego, California**  
(Address of Principal Executive Offices)

**92130**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (858) 558-2871**

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                        | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
|--|----------------------|--|
| Common Stock, par value \$0.0001 per share | ACAD                 | The Nasdaq Stock Market LLC                  |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(c) On December 9, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Mark C. Schneyer as Executive Vice President, Chief Financial Officer. Mr. Schneyer was also appointed as the Company’s principal financial officer. Mr. Schneyer’s responsibilities include the functional areas of finance, accounting, investor relations, and business development.

Mr. Schneyer, age 47, joined the Company in May 2020 as Senior Vice President, Business Development and Chief Business Officer. Since September 2021, he has served as the Company’s Interim Chief Financial Officer. Mr. Schneyer joined Acadia from Pfizer Inc., where he was most recently Vice President, Business Development for the Upjohn division. He joined Pfizer’s Worldwide Business Development organization in 2011 and served in various business development positions of increasing responsibility, overseeing strategic transactions spanning licensing agreements, product acquisitions and divestitures, strategic collaborations and company acquisitions. Prior to Pfizer, Mr. Schneyer was an investment banker at Lazard and advised boards of directors and senior management teams in the healthcare sector. Mr. Schneyer earned a Bachelor of Science in economics with a concentration in finance from the Wharton School of the University of Pennsylvania.

There is no arrangement or understanding between Mr. Schneyer and any other person pursuant to which Mr. Schneyer was selected as an officer, and there are no actual or proposed transactions between the Company and Mr. Schneyer or any related person that would require disclosure under Item 404(a) of Regulation S-K.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

| <u>Exhibit Number</u> | <u>Description</u>   |
|-----------------------|--|
| 99.1                  | <a href="#">Press Release dated December 9, 2021</a>                         |
| 104                   | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Acadia Pharmaceuticals Inc.**

Dated: December 14, 2021

By: /s/ Austin D. Kim

Austin D. Kim

Executive Vice President, General Counsel & Secretary

**Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice  
President, Chief Financial Officer**

SAN DIEGO—(BUSINESS WIRE)— Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately. Mr. Schneyer has served as the company's interim CFO since September 2021, while retaining his responsibilities as Acadia's head of business development and Chief Business Officer. Mr. Schneyer's responsibilities as CFO will include the functional areas of finance, accounting, investor relations, and business development. Mr. Schneyer will continue to report to Steve Davis, Chief Executive Officer, and will remain a member of the company's Executive Management Committee.

"Mark is a highly valuable thought partner who has demonstrated strong leadership across the breadth of our business," said Steve Davis, Chief Executive Officer. "I'm very excited to further leverage Mark's robust experience in corporate finance and strategic transactions as we realize the promise of Acadia's near-term opportunities and execute on our long-term strategy."

Since joining Acadia in 2020, Mr. Schneyer has been instrumental in developing long-term strategic growth initiatives focused on expanding the breadth of transactions the company evaluates. He led the effort to acquire CerSci Therapeutics in late 2020 which brought in a Phase 2 ready pain program with a first-in-class mechanism.

"I look forward to serving as Acadia's CFO and working with our talented teams across the company to drive our continued commercial success, advance our research and development pipeline, expand our portfolio, engage with the investment community, and serve the patients and families who can benefit from our innovative approach to meeting the unmet needs in neuroscience," said Mr. Schneyer.

Mr. Schneyer joined Acadia from Pfizer Inc. where he was most recently Vice President, Business Development for the Upjohn division. He joined Pfizer's Worldwide Business Development organization in 2011 and served in various business development positions of increasing responsibility overseeing strategic transactions spanning licensing agreements, product acquisitions and divestitures, strategic collaborations and company acquisitions. Prior to Pfizer, Mr. Schneyer was an investment banker at Lazard and advised boards of directors and senior management teams in the healthcare sector.

Mr. Schneyer earned a Bachelor of Science in economics with a concentration in finance from the Wharton School of the University of Pennsylvania.

*About Acadia Pharmaceuticals*

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at [www.acadia-pharm.com](http://www.acadia-pharm.com) and follow us on [LinkedIn](#) and [Twitter](#).

**Contacts**

*Media Contact:*

Acadia Pharmaceuticals Inc. Deb Kazenelson  
(818) 395-3043  
[media@acadia-pharm.com](mailto:media@acadia-pharm.com)

*Investor Contact:*

Acadia Pharmaceuticals Inc.  
Mark Johnson, CFA  
(858) 261-2771  
[ir@acadia-pharm.com](mailto:ir@acadia-pharm.com)

Source: Acadia Pharmaceuticals Inc.